Optimizing the Management of Relapsed Refractory Chronic Lymphocytic Leukemia (Part 1)
January 12, 2018
July 12, 2018
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by University of Nebraska Medical Center, Center for Continuing Education in Joint Providership with PlatformQ Health Education, LLC.
Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Verastem.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This program is primarily intended for US-based hematologists, medical oncologists, oncology advance practice providers and nurses, pharmacists, and other clinicians involved in the diagnosis and treatment of CLL. Recruitment efforts will be multipronged and highly targeted to reach the specific specialty constituencies within this audience.
Upon completion of this activity, participants should be able to:
- Evaluate the treatment implications of common mutations and abnormalities such as del(17p), del(11q), and mut TP53 in the relapsed disease setting
- Plan individualized treatment algorithms based on clinical data and patient health status
- Summarize treatment strategies of sequential and combination regimens for relapsed refractory CLL
- Address potential barriers to treatment adherence for CLL
Julie Vose, M.D., M.B.A.
Professor, Internal Medicine
University of Nebraska Medical Center
Susan O'Brien, MD
Associate Director for Clinical Science
UC Irvine Health
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The University of Nebraska Medical Center, Center for Continuing Education designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Julie M. Voss
- Research Grant Support: Acerta Pharma, Bristol–Myers Squibb, Celgene, Incyte Corp., Kite Pharma, Merck Sharp & Dohme Corp., Novartis, Seattle Genetics, Inc.
- Honorarium: Novartis, Abbvie, Epizyme, Roche, Legend Pharmaceuticals
- Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, Abbvie, Alexion
- Research Support: Kite, Regeneron, Acerta
- Consultant/Research Support: Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis
- Lois Colburn, Executive Director: Has nothing to disclose.
- Brenda C. Ram, CMP, CHCP, Coordinator: Has nothing to disclose.
- Anne Roc, PhD, Medical Director: Has nothing to disclose.
- Randi O’Hara, Director, Education and Program Management: Has nothing to disclose.
Instructions for Participation and Credit
There are no fees to participate in this activity. To participate in the activity, go to http://www.OMedLive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive CE credit, participants must receive a minimum score of 70% on the post-test.
Hardware and Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unapproved/Off Label Use
The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantors. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at email@example.com or call 402-559-4152.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.